Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Pharmacokinetics Interaction of Non-Steroid Anti Inflammatory Drugs to 99mTc-MDP Radiopharmaceuticals for Bone Imaging and Its Biodistribution

Atom Indonesia · Vol. 44 No. 3 (2018) · hlm. 173–177

DOI
10.17146/aij.2018.741
ISSN
2356-5322, 0126-1568
Terbit
2018-12-27
Penerbit
National Research and Innovation Agency
Bahasa
eng
Lisensi
creativecommons.org/licenses/by-nc-sa/4.0

Abstrak

99mTc-MDP has been developed as a radiopharmaceutical for bone imaging in nuclear medicine. A drug therapy can alter the pharmacokinetic profiles and biodistribution patterns of radiopharmaceuticals. To achieve an optimum diagnostic outcome, this research focused on pharmacokinetics interaction between two kinds of nonsteroidal anti-inflammatory drugs (NSAID) drugs, meloxicam and sodium diclofenac with 99mTc-MDP using mice(Mus musculus). Therewerefive groups of animal modeland each group consists of three mice except for group II and III which consists of six mice. The groups were classified asuntreated mice (I), mice treated withmeloxicam for 3 days (II), treated with sodium diclofenac for 3 days (III), treated with meloxicam once or at onset (IV), and mice with sodium diclofenac once or at onset (V). Pharmacokinetics interaction and biodistribution test were conducted by injecting 100 µCi/100 µL 99mTc-MDP intravenously. Blood samples were withdrawn from each mouse which were then weighted and counted using single channel analyzer. The %ID/g of 99mTc-MDP in blood of untreated mice (I), mice treated with meloxicam (II) and sodium diclofenac (III) 5 minutes post injection were 3.71, 8.96 and 9.15 % respectively, then decrease to 0.12, 0.01, and 0.01 %, respectively, 24 hours post injection. The results of T-test showed there were no significant differences in distribution of 99mTc-MDP in untreated mice (I) and in treated mice either with meloxicam (II) or sodium diclofenac (III). However, there was significant difference in elimination of 99mTc-MDP in untreated mice (I) and in treated mice either with meloxicam (II) or sodium diclofenac (III). The bone uptakes of 99mTc-MDP were 9.03 ± 0.41, 3.52 + 0.52, 3.62 + 0.45, 8.44 + 1.39, and 8.09 ± 0.86 % in group I, II, III, IV, and V, respectively. T-test showed there were significant differences in bone uptake of 99mTc-MDP in mice with previously treated with meloxicam and sodium diclofenac for 3 days. From these result, it can be concluded that anadministration of meloxicam and sodium diclofenac could accelerate elimination half-life that cause low uptake of 99mTc-MDP radiopharmaceuticalon the bone as the primary target. Therefore, it is necessary to follow up using image study to determine the significance of the effects on image quality.

Kata kunci

Jaringan kolaborasi para penulis

20 penulis · 50 tautan kepenulisan bersama · 26 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • National Nuclear Energy Agency of Indonesia
  • Universitas Bakti Tunas Husada
  • Sekolah Tinggi Farmasi Indonesia
  • Bandung Institute of Technology
  • Nuclear Energy Agency
  • Padjadjaran University
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Witri NuraeniNational Nuclear Energy Agency of Indonesia2
T. H. AmbarwibawaNuclear Energy Agency2
A. HanafiahSekolah Tinggi Farmasi Indonesia1
Maula Eka SriyaniNational Nuclear Energy Agency of Indonesia1
Nanny Kartini OekarNational Nuclear Energy Agency of Indonesia1
Nurlaila ZainuddinNational Nuclear Energy Agency of Indonesia1
Z NurlailaNational Nuclear Energy Agency of Indonesia1
Heni RachmawatiBandung Institute of Technology1
Aang Hanafiah WangsaatmadjaNational Nuclear Energy Agency of Indonesia1
DEBBIE SOEFIE RETNONINGRUMBandung Institute of Technology1
Veronika Yulianti SusiloNational Nuclear Energy Agency of Indonesia1
Ruswanto RuswantoUniversitas Bakti Tunas Husada1
Anindita Tri Kusuma PratitaUniversitas Bakti Tunas Husada1
Febby PratamaUniversitas Bakti Tunas Husada1
Tita NofiantiUniversitas Bakti Tunas Husada1
Holis Abdul HolikPadjadjaran University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://atomindonesia.brin.go.id/index.php/aij/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Pharmacokinetics Interaction of Non-Steroid Anti Inflammatory Drugs to 99mTc-MDP Radiopharmaceuticals for Bone Imaging and Its Biodistribution</dc:title>
	<dc:creator>Mahendra, I.</dc:creator>
	<dc:creator>Daruwati, I.</dc:creator>
	<dc:creator>Halimah, I.</dc:creator>
	<dc:creator>Pajrin, S.R.</dc:creator>
	<dc:subject xml:lang="en-US">Pharmacokinetics interaction; Biodistribution; 99mTc-MDP; Meloxicam; Sodium diclofenac</dc:subject>
	<dc:description xml:lang="en-US">99mTc-MDP has been developed as a radiopharmaceutical for bone imaging in nuclear medicine. A drug therapy can alter the pharmacokinetic profiles and biodistribution patterns of radiopharmaceuticals. To achieve an optimum diagnostic outcome, this research focused on pharmacokinetics interaction between two kinds of nonsteroidal anti-inflammatory drugs (NSAID) drugs, meloxicam and sodium diclofenac with 99mTc-MDP using mice(Mus musculus). Therewerefive groups of animal modeland each group consists of three mice except for group II and III which consists of six mice. The groups were classified asuntreated mice (I), mice treated withmeloxicam for 3 days (II), treated with sodium diclofenac for 3 days (III), treated with meloxicam once or at onset (IV), and mice with sodium diclofenac once or at onset (V). Pharmacokinetics interaction and biodistribution test were conducted by injecting 100 µCi/100 µL 99mTc-MDP intravenously. Blood samples were withdrawn from each mouse which were then weighted and counted using single channel analyzer. The %ID/g of 99mTc-MDP in blood of untreated mice (I), mice treated with meloxicam (II) and sodium diclofenac (III) 5 minutes post injection were 3.71, 8.96 and 9.15 % respectively, then decrease to 0.12, 0.01, and 0.01 %, respectively, 24 hours post injection. The results of T-test showed there were no significant differences in distribution of 99mTc-MDP in untreated mice (I) and in treated mice either with meloxicam (II) or sodium diclofenac (III). However, there was significant difference in elimination of 99mTc-MDP in untreated mice (I) and in treated mice either with meloxicam (II) or sodium diclofenac (III). The bone uptakes of 99mTc-MDP were 9.03 ± 0.41, 3.52 + 0.52, 3.62 + 0.45, 8.44 + 1.39, and 8.09 ± 0.86 % in group I, II, III, IV, and V, respectively. T-test showed there were significant differences in bone uptake of 99mTc-MDP in mice with previously treated with meloxicam and sodium diclofenac for 3 days. From these result, it can be concluded that anadministration of meloxicam and sodium diclofenac could accelerate elimination half-life that cause low uptake of 99mTc-MDP radiopharmaceuticalon the bone as the primary target. Therefore, it is necessary to follow up using image study to determine the significance of the effects on image quality.</dc:description>
	<dc:publisher xml:lang="en-US">National Research and Innovation Agency</dc:publisher>
	<dc:contributor xml:lang="en-US"></dc:contributor>
	<dc:date>2018-12-27</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US"></dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://atomindonesia.brin.go.id/index.php/aij/article/view/741</dc:identifier>
	<dc:identifier>10.17146/aij.2018.741</dc:identifier>
	<dc:source xml:lang="en-US">Atom Indonesia; Vol 44, No 3 (2018): December 2018; 173-177</dc:source>
	<dc:source>2356-5322</dc:source>
	<dc:source>0126-1568</dc:source>
	<dc:source>10.55981/aij.v44i3</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/view/741/640</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/741/768</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/741/808</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/741/923</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/741/922</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/741/927</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/741/957</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/741/958</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/741/969</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/741/1219</dc:relation>
	<dc:relation>https://atomindonesia.brin.go.id/index.php/aij/article/downloadSuppFile/741/1237</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2018 Atom Indonesia</dc:rights>
	<dc:rights xml:lang="en-US">http://creativecommons.org/licenses/by-nc-sa/4.0</dc:rights>
</oai_dc:dc>